• Je něco špatně v tomto záznamu ?

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

P. Ghia, A. Pluta, M. Wach, D. Lysak, T. Kozak, M. Simkovic, P. Kaplan, I. Kraychok, A. Illes, J. de la Serna, S. Dolan, P. Campbell, G. Musuraca, A. Jacob, E. Avery, JH. Lee, W. Liang, P. Patel, C. Quah, W. Jurczak

. 2020 ; 38 (25) : 2849-2861. [pub] 20200527

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012215

PURPOSE: Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). METHODS: Eligible patients, aged ≥ 18 years with R/R CLL, were randomly assigned 1:1 centrally and stratified by del(17p) status, Eastern Cooperative Oncology Group performance status score, and number of prior lines of therapy. Patients received acalabrutinib monotherapy or investigator's choice (idelalisib plus rituximab [I-R] or bendamustine plus rituximab [B-R]). The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC) in the intent-to-treat population. Key secondary end points included IRC-assessed overall response rate, overall survival, and safety. RESULTS: From February 21, 2017, to January 17, 2018, a total of 398 patients were assessed for eligibility; 310 patients were randomly assigned to acalabrutinib monotherapy (n = 155) or investigator's choice (n = 155; I-R, n = 119; B-R, n = 36). Patients had received a median of two prior therapies (range, 1-10). After a median follow-up of 16.1 months (range, 0.03-22.4 months), median PFS was significantly longer with acalabrutinib monotherapy (PFS not reached) compared with investigator's choice (16.5 months [95% CI, 14.0 to 17.1 months]; hazard ratio, 0.31 [95% CI, 0.20 to 0.49]; P < .0001). Estimated 12-month PFS was 88% (95% CI, 81% to 92%) for acalabrutinib and 68% (95% CI, 59% to 75%) for investigator's choice. Serious adverse events occurred in 29% of patients (n = 44 of 154) treated with acalabrutinib monotherapy, 56% (n = 66 of 118) with I-R, and 26% (n = 9 of 35) with B-R. Deaths occurred in 10% (n = 15 of 154), 11% (n = 13 of 118), and 14% (n = 5 of 35) of patients receiving acalabrutinib monotherapy, I-R, and B-R, respectively. CONCLUSION: Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012215
003      
CZ-PrNML
005      
20210507103119.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.19.03355 $2 doi
035    __
$a (PubMed)32459600
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ghia, Paolo $u Università Vita-Salute San Raffaele, Milano, Italy $u Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milano, Italy
245    10
$a ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia / $c P. Ghia, A. Pluta, M. Wach, D. Lysak, T. Kozak, M. Simkovic, P. Kaplan, I. Kraychok, A. Illes, J. de la Serna, S. Dolan, P. Campbell, G. Musuraca, A. Jacob, E. Avery, JH. Lee, W. Liang, P. Patel, C. Quah, W. Jurczak
520    9_
$a PURPOSE: Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). METHODS: Eligible patients, aged ≥ 18 years with R/R CLL, were randomly assigned 1:1 centrally and stratified by del(17p) status, Eastern Cooperative Oncology Group performance status score, and number of prior lines of therapy. Patients received acalabrutinib monotherapy or investigator's choice (idelalisib plus rituximab [I-R] or bendamustine plus rituximab [B-R]). The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC) in the intent-to-treat population. Key secondary end points included IRC-assessed overall response rate, overall survival, and safety. RESULTS: From February 21, 2017, to January 17, 2018, a total of 398 patients were assessed for eligibility; 310 patients were randomly assigned to acalabrutinib monotherapy (n = 155) or investigator's choice (n = 155; I-R, n = 119; B-R, n = 36). Patients had received a median of two prior therapies (range, 1-10). After a median follow-up of 16.1 months (range, 0.03-22.4 months), median PFS was significantly longer with acalabrutinib monotherapy (PFS not reached) compared with investigator's choice (16.5 months [95% CI, 14.0 to 17.1 months]; hazard ratio, 0.31 [95% CI, 0.20 to 0.49]; P < .0001). Estimated 12-month PFS was 88% (95% CI, 81% to 92%) for acalabrutinib and 68% (95% CI, 59% to 75%) for investigator's choice. Serious adverse events occurred in 29% of patients (n = 44 of 154) treated with acalabrutinib monotherapy, 56% (n = 66 of 118) with I-R, and 26% (n = 9 of 35) with B-R. Deaths occurred in 10% (n = 15 of 154), 11% (n = 13 of 118), and 14% (n = 5 of 35) of patients receiving acalabrutinib monotherapy, I-R, and B-R, respectively. CONCLUSION: Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a bendamustin hydrochlorid $x aplikace a dávkování $x škodlivé účinky $7 D000069461
650    _2
$a benzamidy $x škodlivé účinky $x terapeutické užití $7 D001549
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x patologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a puriny $x aplikace a dávkování $x škodlivé účinky $7 D011687
650    _2
$a pyraziny $x škodlivé účinky $x terapeutické užití $7 D011719
650    _2
$a chinazolinony $x aplikace a dávkování $x škodlivé účinky $7 D052999
650    _2
$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pluta, Andrzej $u Szpital Specjalistyczny w Brzozowie im. Ks. Markiewicza, Oddział Hematologii Onkologicznej z Klinicznym Oddziałem Przeszczepiania Szpiku, Brzozow, Poland
700    1_
$a Wach, Malgorzata $u Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
700    1_
$a Lysak, Daniel $u Fakultní Nemocnice Plzeň, Pilsen, Czech Republic
700    1_
$a Kozak, Tomas $u Fakultní Nemocnice Královske Vinohrady, Prague, Czech Republic
700    1_
$a Simkovic, Martin $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Kaplan, Polina $u Dnipropetrovsk City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine
700    1_
$a Kraychok, Iryna $u National Cancer Institute, Kiev, Ukraine
700    1_
$a Illes, Arpad $u University of Debrecen, Faculty of Medicine, Department of Hematology, Debrecen, Hungary
700    1_
$a de la Serna, Javier $u Hospital Universitario 12 de Octubre, Madrid, Spain
700    1_
$a Dolan, Sean $u Saint John Regional Hospital, University of New Brunswick, St John, New Brunswick, Canada
700    1_
$a Campbell, Phillip $u Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia
700    1_
$a Musuraca, Gerardo $u Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy
700    1_
$a Jacob, Abraham $u Royal Wolverhampton Hospital National Health Service Trust, Wolverhampton, United Kingdom
700    1_
$a Avery, Eric $u Nebraska Hematology Oncology, Lincoln, NE
700    1_
$a Lee, Jae Hoon $u Gachon University Gil Medical Center, Incheon, Republic of Korea
700    1_
$a Liang, Wei $u Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA
700    1_
$a Patel, Priti $u Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA
700    1_
$a Quah, Cheng $u Acerta Pharma (a member of the AstraZeneca group), South San Francisco, CA
700    1_
$a Jurczak, Wojciech $u Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 38, č. 25 (2020), s. 2849-2861
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32459600 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103118 $b ABA008
999    __
$a ok $b bmc $g 1650564 $s 1132594
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 25 $d 2849-2861 $e 20200527 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace